Drug Approval | June 12, 2022
China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
Tislelizumab is now approved in nine indications in China
Tislelizumab is now approved in nine indications in China
New Director supports NASDAQ rule on diversity
Healthcare is timely and personal – and its delivery should be too
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
A research group led by Ben-Gurion University of the Negev managed to produce an innovative microchip for creating sperm in a culture by using a microfluidic system.
Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Subscribe To Our Newsletter & Stay Updated
